Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × NSCLC × Aspirin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 22 Colonic Neoplasms 12 Breast Neoplasms 11 Neoplasms 10 Prostatic Neoplasms 8 Polycythemia Vera 8 Venous Thromboembolism 7 Multiple Myeloma 6 Recurrence 5 Rectal Neoplasms 5 Ovarian Neoplasms 4 Neoplasms, Plasma Cell 4 Neoplasm Metastasis 4 Myeloproliferative Disorders 4 Barrett Esophagus 4 Thrombocythemia, Essential 3 Precancerous Conditions 3 Melanoma 3 Esophageal Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Adenomatous Polyps 3 Adenoma 3 Thrombosis 2 Thromboembolism 2 Smoking Cessation 2 Sarcoma 2 Primary Myelofibrosis 2 Neoplastic Cells, Circulating 2 Neoplasms by Site 2 Myocardial Infarction 2

Interventions

Pemetrexed 11 Carboplatin 11 osimertinib 10 aflutinib 8 Drug Therapy 8 Gefitinib 7 Radiotherapy 6 anlotinib 5 Docetaxel 5 Cisplatin 5 Vinorelbine 4 Radiosurgery 4 Paclitaxel 4 Gemcitabine 4 tislelizumab 3 pembrolizumab 3 icotinib 3 apatinib 3 HM781-36B 3 Erlotinib Hydrochloride 3 toripalimab 2 spartalizumab 2 rezivertinib 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2 Immune Checkpoint Inhibitors 2 HMPL-013 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02387086 2015-03-12

Gefitinib Combined With Thalidomide to Treat NSCLC

Shaanxi Provincial People's Hospital

Phase 2/3 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡